Alpine Immune Sciences, Inc. (ALPN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Seattle, WA, アメリカ. 現CEOは Mitchell H. Gold.
ALPN を有する IPO日 2015-06-17, 142 名の正社員, に上場 NASDAQ Global Market, 時価総額 $4.46B.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to treat cancer, autoimmune disorders, and inflammatory diseases. The company's pipeline includes ALPN-101, an ICOS/CD28 antagonist for autoimmune and inflammatory conditions; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for cancer treatment; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated diseases. Alpine has established strategic collaborations with AbbVie Ireland for ALPN-101 development and with Adaptimmune Therapeutics for next-generation SPEAR T cell products. Founded in 2007 and headquartered in Seattle, Washington, the company leverages its immunotherapy expertise to address significant unmet medical needs across multiple therapeutic areas.
